Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lyber+ is a multi-ingredient nutraceutical supplement developed and marketed by Anglo-French Drugs & Industries (AFDIL). It is formulated to support vitality, energy levels, and overall health, particularly in the context of male reproductive wellness and general metabolic support. The product contains a synergistic blend of antioxidants and micronutrients, including Coenzyme Q10 (Ubidecarenone), L-Carnitine L-Tartrate, Lycopene, Astaxanthin, Zinc, and Selenium. These components work to enhance mitochondrial function, improve cellular energy production, and protect tissues from oxidative damage. Lyber+ is typically used as a dietary supplement to manage fatigue, support energy metabolism, and provide nutritional support for various physiological functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lyber+.